Product Center
The launch meeting of the safety evaluation research project for the tetravalent influenza virus subunit vaccine after its launch was a complete success
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-25
- Views:
(Summary description)Recently, the launch meeting of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine post market safety evaluation research project was held in Lanzhou, Gansu.
The launch meeting of the safety evaluation research project for the tetravalent influenza virus subunit vaccine after its launch was a complete success
(Summary description)Recently, the launch meeting of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine post market safety evaluation research project was held in Lanzhou, Gansu.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-25 14:16
- Views:
Recently, the launch meeting of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine post market safety evaluation research project was held in Lanzhou, Gansu.
The post marketing safety evaluation research project of the tetravalent influenza virus subunit vaccine is a multicenter study led by the Jiangsu Provincial Center for Disease Control and Prevention, guided by the Jiangsu Provincial Center for Adverse Drug Reaction Monitoring, and jointly participated by the six provincial centers for disease control and prevention. The purpose is to evaluate the safety of the tetravalent influenza virus subunit vaccine after vaccination in an expanded population of 3 years old and above, improve the safety monitoring model for Chinese vaccines after market launch, establish a long-term active monitoring mechanism, and promote the vaccine regulatory system to move towards higher maturity goals.
Relevant information
-
Ab&B Bio and Yither Bio have both obtained qualification certification!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively. - The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held 12-25
- Influenza virus subunit vaccine (adjuvant) IND application approved 10-30
- The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
